News Transgene

Equities

TNG

FR0005175080

Real-time Euronext Paris Other stock markets 03:06:41 2024-04-25 am EDT			5-day change	1st Jan Change
1.344 ^EUR	-0.15%		-7.69%	-1.90%

Apr. 10	Transgene: presents vaccine results at AACR	CF
Mar. 28	Transgene CFO Steps Down; Successor Assumes Office	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024	Apr. 24	GL
Availability of Transgene's 2023 Universal Registration Document	Apr. 11	GL
Transgene: presents vaccine results at AACR	Apr. 10	CF
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024	Apr. 09	GL
Transgene CFO Steps Down; Successor Assumes Office	Mar. 28	MT
Transcript : Transgene SA, 2023 Earnings Call, Mar 27, 2024	Mar. 27
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025	Mar. 27	GL
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer	Mar. 27	GL
Transgene SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Transgene SA Announces Chief Financial Officer Changes	Mar. 27	CI
Transgene SA Promotes Christelle Schwoerer to Chief Human Resources Officer, Effective from April 1, 2024, and She Also Joins the Executive Committee	Mar. 27	CI
Transgene Announces Upcoming Investor Meetings	Mar. 18	GL
Transgene Announces Upcoming Investor Meetings	Mar. 18	AQ
Fractyl Health Reports 'Promising' Preclinical Findings From Rejuva Platform; Shares Fall	Mar. 12	MT
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024	Mar. 06	GL
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024	Mar. 06	AQ
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050	Mar. 05	BU
Transgene, NEC Corporation and BostonGene Corporation Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050	Mar. 05	CI
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050	Mar. 05	GL
Transgene Appoints Chief Business Officer	Jan. 23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Transgene

Equities

TNG

FR0005175080

Summary

Filters